Medline (NASDAQ:MDLN) Given New $45.00 Price Target at Stifel Nicolaus

Medline (NASDAQ:MDLN) had its price target dropped by stock analysts at Stifel Nicolaus from $50.00 to $45.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price points to a potential upside of 27.86% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. BNP Paribas Exane decreased their price objective on shares of Medline from $49.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Sanford C. Bernstein decreased their price target on shares of Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Tigress Financial increased their target price on Medline from $60.00 to $62.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Citigroup dropped their price target on Medline from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $47.00 target price on shares of Medline in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Medline has a consensus rating of “Moderate Buy” and an average price target of $49.42.

Medline Price Performance

MDLN traded down $1.48 during trading on Thursday, hitting $35.20. The company’s stock had a trading volume of 1,092,740 shares, compared to its average volume of 7,281,322. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. Medline has a twelve month low of $32.81 and a twelve month high of $50.88. The business’s fifty day simple moving average is $38.29 and its 200 day simple moving average is $41.83. The firm has a market capitalization of $46.24 billion and a price-to-earnings ratio of 109.88.

Medline (NASDAQ:MDLN) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. On average, equities research analysts forecast that Medline will post 1.49 EPS for the current fiscal year.

Insider Activity

In other news, insider Douglas P. Golwas sold 100,000 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the sale, the insider directly owned 23,899 shares in the company, valued at approximately $878,766.23. This trade represents a 80.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jessi L. Corcoran bought 5,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were bought at an average cost of $34.15 per share, with a total value of $170,750.00. Following the completion of the purchase, the insider directly owned 5,000 shares in the company, valued at $170,750. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

Institutional investors have recently added to or reduced their stakes in the business. Sound Income Strategies LLC purchased a new position in Medline during the 4th quarter worth approximately $25,000. Entrust Financial LLC acquired a new stake in shares of Medline in the 4th quarter worth $26,000. GAMMA Investing LLC boosted its holdings in shares of Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after acquiring an additional 254 shares in the last quarter. NBC Securities Inc. purchased a new position in Medline during the fourth quarter worth about $28,000. Finally, Whipplewood Advisors LLC purchased a new stake in shares of Medline in the first quarter valued at about $30,000.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Revenue growth and adjusted earnings beat expectations. Medline reported second-quarter sales of $7.685 billion, up 11.6% year over year, and adjusted diluted EPS of $0.50 versus the $0.32 consensus estimate. Adjusted EBITDA rose 13.4% to $1.06 billion, supported by existing-customer growth and new customer implementations. Medline Reports Second Quarter and First Six Months 2026 Results
• Positive Sentiment: Medline raised its organic-sales outlook. Management now expects 2026 organic sales growth of 9% to 10%, up from 8.5% to 9.5%, citing strong demand and new customer signings. Operating cash flow increased 28.2% to $1.13 billion in the first half. Medline raises 2026 organic sales outlook
• Positive Sentiment: Analyst support remains bullish. BTIG reiterated a Buy rating and maintained a $55 price target, viewing the company’s growth as durable and the current cost pressures as transitory. Medline BTIG Buy rating and price target
• Neutral Sentiment: The Tracy, California distribution-center fire caused a $336 million loss before expected insurance recoveries. Management characterized the disruption as manageable, but investors may remain focused on execution and recovery timing.
• Negative Sentiment: The key disappointment was guidance. Medline cut its 2026 adjusted EBITDA forecast to $3.3 billion-$3.4 billion from $3.5 billion-$3.6 billion, citing inflation, Middle East-related costs, investments to support demand, quality remediation and retail weakness. GAAP net income fell 58.3% to $139 million, and the quarter benefited from $243 million of tariff refunds, raising concerns about underlying earnings quality. Medline falls despite Q2 beat after EBITDA outlook cut
• Negative Sentiment: A law firm announced an investigation into possible securities-law violations. No findings or formal claims were disclosed, but the announcement adds headline and litigation risk. Kaplan Fox Medline investigation announcement

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.